First Generic Versions of Lyrica Approved by FDA – Pain Medicine News – based on a press release from the FDA – July 2019
The FDA approved the first generic versions of the pain medication pregabalin, the agency announced. It accepted multiple applications, granting approvals to nine manufacturers, including Teva Pharmaceuticals.
I have to wonder why *nine* manufacturers are lined up to sell this medication. Competition “should” lower the price, but that’s not how things work in pharmaceutical pricing.
Currently manufactured by Pfizer as Lyrica, pregabalin is a gabapentinoid indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia and neuropathic pain associated with spinal cord injury.
Pregabalin was initially developed as an antiepileptic medication.
And it’s probably much more effective as an antiepileptic medication than as a pain medication.
In recent years, recommendations and guidelines have encouraged the use of pregabalin, along with other nonopioid medications, as first-line treatment for neuropathic pain, such as in postherpetic neuralgia.
Guidelines have encouraged the use of medications that are most often ineffective for our chronic pain. It seems like any drug that’s not an opioid is “recommended”, whether it works or not.
Studies have also shown pain relief benefits from prescribing pregabalin in combination with gabapentin for neuropathic pain.
That’s the first I’ve heard of this combination.